As N‐cadherin antagonists have been shown to overcome bone marrow stromal cell‐mediated resistance to chemotherapeutic agents in chronic myeloid leukemia cells,88, 89 we therefore cannot exclude the possibility that LCRF‐0006 treatment may disrupt MM tumor cell interactions with the supportive bone marrow niche in vivo, thereby increasing tumor cell sensitivity to bortezomib. This evidence concerns the gene CDH2 and chronic myelogenous leukemia, BCR-ABL1 positive.